The costs and consequences of multiple sclerosis relapses: A managed care perspective

Journal of the Neurological Sciences

Volumn 256, Issue SUPPL. 1, 2007, Pages

  Morrow, Thomas J ^a  

^a National Association of Managed Care Physicians   (United States)

Author keywords

Costs; Economics; Exacerbation; Insurance; Managed care; MS; Multiple sclerosis; Relapse

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE;

ARTICLE; CAREGIVER; CHRONIC DISEASE; COMORBIDITY; DISABILITY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; IMMUNOMODULATION; MANAGED CARE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE;

DISEASE MANAGEMENT; DISEASE PROGRESSION; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; IMMUNOLOGIC FACTORS; INSURANCE, HEALTH; MANAGED CARE PROGRAMS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE;

EID: 34147127556     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.01.063     Document Type: Article

References (19)

1. The Henry J. Kaiser Family Foundation. Trends and Indicators in the Changing Health Care Marketplace. Publication number 7031. Available at: http://www.kff.org/insurance/7031/index.cfm. Accessed December 30, 2005.
2. The Henry J. Kaiser Family Foundation. Employer Health Benefits 2006 Annual Survey Publication number 7527. Available at: http://www.kff.org/insurance/7527/. Accessed November 27, 2006.
3. The Commonwealth Fund. The Commonwealth Fund 2003 National Survey of Physicians and Quality of Care. Available at: http://www.cmwf.org/surveys/surveys_show.htm?doc_id=278869. Accessed August 15, 2005.
4. National Committee for Quality Assurance (NCQA). The State of Managed Care Quality 2005. Available at: http://www.ncqa.org/Communications/News/SOHC_2005.htm. Accessed March 3, 2006.
5. Morrow T., Brown J., Smith C., and Thrower B. Considerations for the treatment of multiple sclerosis in the managed care setting. Formulary 38 (2003) 646-655
6. Morrow T., and Thrower B. Immunomodulatory therapy for multiple sclerosis: glatiramer acetate. J Manag Care Med 7 (2004) 14-23
7. Lublin F.D., Baier M., and Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61 (2003) 1528-1532
8. Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci in press, doi:10.1016/j.jns.2007.01.065.
9. O'Brien J.A., Ward A.J., Patrick A.R., and Caro J. Cost of managing an episode of relapse in multiple sclerosis in the US. BMC Health Serv Res 3 (2003) 17-29
10. Grudzinski A.N., Hakim Z., Cox E.R., Labiner D.M., and Bootman J.L. Economic assessment of the relationship between disease exacerbations and the cost of multiple sclerosis. J Managed Care Pharm 6 (2000) 19-24
11. National MS Society. The National MS Society's Consensus Statement. Available at: http://www.nationalmssociety.org/Sourcebook-Early.asp. Accessed March 3, 2006.
12. Lacy J.R., Stuart W.H., Jacobs L.D., Vartanian T., Philips T., Greenstein J.I., et al. Registry of Multiple Sclerosis Treatment and Care (MSTRAC). Patient and physician characteristics. Int J MS Care 2 (2000) 25-36
13. Grima D.T., Torrance G.W., Francis G., Rice G., Rosner A.J., and Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 6 (2000) 91-98
14. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis; an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
15. Bashir K., Buchwald L., Coyle P.K., Freedman M., Jeffery D., Markowitz C., et al. MS patient management: optimizing immunomodulatory therapy for MS patients. Int J MS Care 4 (2002) S1-S7 [suppl]
16. Freedman M.S., Paltry D.G., Grand'Maison F., Myles M.L., Paty D.W., and Selchen D.H. Canadian MS Working Group. Treatment optimization in multiple sclerosis. Can J Neurol Sci 31 (2004) 157-168
17. Thygesen P. Evaluation of drug treatment of disseminated sclerosis. [Danish]. Ugeskr Laeger 127 (1965) 1448-1450
18. Goldstein I., Siroky M.B., Sax D.S., and Krane R.J. Neurologic abnormalities in multiple sclerosis. J Urol 128 (1982) 541-545
19. Urinary dysfunction and multiple sclerosis: evidence-based management strategies for urinary dysfunction in multiple sclerosis (1999), Multiple Sclerosis Council for Clinical Practice Guidelines, Washington, DC